Nortech Systems Incorporated — FY2015 Form 10-K Summary
Business context and reporting period
Nortech Systems is a single-segment electronic manufacturing services company serving aerospace and defense, medical/life sciences, and industrial customers. It provides engineering, design, testing, prototyping, manufacturing, supply-chain management, and post-market services from facilities in the United States, Mexico, and China.
The filing covers the fiscal year ended December 31, 2015, with comparative results for 2014. The consolidated financial statements were audited by RSM US LLP, which issued an unqualified opinion. Management concluded that disclosure controls and internal control over financial reporting were effective.
Key financial metrics
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Net sales | $115.2 million | $112.0 million | +2.8% |
| Gross profit | $12.1 million | $13.3 million | -$1.3 million |
| Gross margin | 10.5% | 11.9% | -1.4 percentage points |
| Operating income (loss) | $(0.4) million | $1.3 million | Declined |
| Net income (loss) | $(0.6) million | $0.9 million | Declined |
| Diluted EPS | $(0.21) | $0.32 | Declined |
| Cash flow from operations | $3.4 million | $1.6 million | +$1.8 million |
| Capital expenditures | $1.7 million | $2.2 million | Declined |
| Cash balance | $0.9 thousand | $66.4 thousand | Declined |
Industrial sales increased 7% to $59.4 million. Aerospace and defense sales declined 3% to $14.5 million, while medical/life sciences sales were essentially flat at $41.3 million. Selling expenses were $5.2 million and general and administrative expenses were $7.2 million.
At December 31, 2015, total assets were $56.6 million and shareholders’ equity was $22.3 million. Accounts receivable were $18.4 million and inventories were $20.2 million. The cash conversion cycle improved to 76 days from 89 days, primarily because of extended supplier payment terms.
Debt and liquidity
- The company had $7.7 million outstanding on a $15.0 million Wells Fargo revolving credit facility, with approximately $6.1 million of net unused availability at year-end, subject to borrowing-base requirements and lender discretion.
- Long-term debt totaled $7.5 million, including $1.5 million of current maturities, compared with $4.8 million at December 31, 2014.
- The company also issued two 4% seller-financed notes related to the Devicix acquisition, with principal amounts of $1.0 million and $1.3 million.
- Management stated that financing arrangements and anticipated operating cash flows should satisfy working-capital needs, capital expenditures, and debt repayments for the foreseeable future.
- The company was in compliance with its credit covenants at December 31, 2015. The fixed-charge coverage requirement was 1.20 to 1.00 for the year-end measurement period and 1.15 to 1.00 thereafter.
- No cash dividends or share repurchases occurred in 2015, and management did not expect to pay dividends in the foreseeable future.
Material changes versus 2014
- Net sales increased $3.2 million, driven mainly by stronger industrial demand and the acquired design-engineering business.
- Gross margin fell because of customer, product, and market mix, new-part start-up costs, and ramp-up costs associated with the Mexico expansion.
- The company moved from $0.9 million of net income to a $0.6 million net loss. The deterioration reflected lower gross profit, acquisition costs, and business-expansion investments, partially offset by a $0.4 million increase in income-tax benefit.
- Operating cash flow increased to $3.4 million, but investing cash use increased to $3.7 million because of the Devicix acquisition and property-and-equipment purchases.
- On July 1, 2015, Nortech acquired substantially all assets of Devicix, LLC for approximately $5.1 million, including $2.0 million of cash, seller notes, and contingent consideration. Devicix contributed approximately $2.5 million of sales and $0.3 million of pretax income after acquisition.
- The acquisition added approximately $3.2 million of goodwill and $2.1 million of finite-lived intangible assets. Management concluded that goodwill was not impaired in its fourth-quarter 2015 test.
- The company expanded its Mexico operation by 50% and leased a 30,000-square-foot facility in Suzhou, China, with operations expected to begin in the second half of 2016.
- The 90-day backlog increased 20% to $20.7 million, led by aerospace and defense and medical/life sciences. Industrial backlog declined 8% to $7.1 million.
Outlook, commentary, risks, and unusual items
The filing does not provide formal earnings or revenue guidance. Management emphasized continued supply-chain and lean-manufacturing initiatives, customer diversification, expansion of regional and global production capabilities, and potential future acquisitions, mergers, or joint ventures.
- Management cited the strong U.S. dollar, weak oil and gas markets, varying global economic conditions, competitive pricing pressure, and customer mix as factors affecting results.
- The largest customer’s two divisions represented 27% of 2015 net sales, compared with 29% in 2014; the customer represented 17% of year-end accounts receivable.
- Component shortages, extended lead times, material-cost inflation, customer cancellations, rescheduled orders, and excess or obsolete inventory could pressure margins and cash flow.
- Medical-device operations are subject to FDA registration, inspections, and Quality System Regulation requirements. Noncompliance could adversely affect operations.
- Foreign operations expose the company to currency, political, labor, transportation, crime, weather, and operational risks in Mexico and China.
- The credit facility is secured by substantially all company assets. Failure to meet financial covenants could restrict borrowing or accelerate repayment obligations.
- The Devicix transaction includes earnout consideration based on eligible engineering and production revenue, with a maximum potential payment of $2.5 million; the recorded fair value of contingent consideration was approximately $0.9 million at acquisition.
- Future minimum operating lease payments totaled approximately $3.7 million. The company stated that ordinary-course legal proceedings were not expected to have a material effect.
Most important facts for investors to verify
- Whether the Devicix acquisition and Suzhou expansion generate sufficient growth and margin improvement to offset integration, amortization, and ramp-up costs.
- Whether gross margin recovers from 10.5% and whether the company returns to sustainable operating profitability.
- Actual availability and borrowing-base capacity under the revolving credit facility, together with compliance with the fixed-charge coverage covenant.
- Customer concentration, renewal and order trends, and the sustainability of the $20.7 million 90-day backlog.
- Inventory quality, receivable collections, and the adequacy of the $0.7 million inventory reserve and $0.3 million doubtful-account allowance.
- Potential earnout payments, seller-note obligations, lease commitments, and other cash requirements associated with the acquisition and international expansion.
- Exposure to component shortages, foreign-market disruption, FDA compliance issues, cybersecurity incidents, environmental liabilities, and product-liability claims.